DGL · 400 mg

- Provides DGL in the form of chewable tablets, the form associated with the greatest clinical effectiveness, because it allows the licorice to be released into the stomach and dispersed/absorbed by the gastric mucosa.
- Offers 400 mg of DGL per tablet, the clinically effective dose.
- Deglycyrrhizination prevents adverse effects associated with licorice consumption.
- Pleasant-tasting tablets for better compliance
- Suitable for vegetarians/vegans
Deglycyrrhizinated licorice, or DGL, has been used clinically for decades, primarily for the treatment of peptic ulcers. Licorice contains numerous triterpenoids and hundreds of flavonoids that have been shown to inhibit several inflammatory enzymes, including cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX). These enzymes decrease the production of several potent inflammatory compounds, including IL-6, prostaglandin E2, thromboxane B2, and leukotriene B4. It is important to note that this inhibition is not primarily due to glycyrrhizic acid, the component of licorice that was eliminated in DGL and is associated with mineralocorticoid excess and hypertension. Licorice contains numerous active compounds with anti-inflammatory, antimicrobial and anti-allergic actions, including glabridin and at least seven licochalcones. These compounds have been shown to prevent lipopolysaccharide (LPS)-induced production of inflammatory compounds, inhibit yeast and bacterial biofilm formation, and stimulate antioxidant enzymes.
In the clinic, DGL has been shown to be comparable in effectiveness to cimetidine in healing and preventing recurrence of ulcers. Furthermore, licorice extracts have been shown to inhibit the adhesion of H. pylori to the gastric mucosa, as well as the growth of antibiotic-resistant strains, suggesting multiple mechanisms of action for its anti-ulcer effect. The use of chewable tablets appears necessary for the effectiveness of DGL, as they allow distribution and absorption through the gastric mucosa.